Engineering Antibodies for Targeted Delivery of PROTACs

PROTACs are a promising new technology for targeted degradation of a wide variety of proteins associated with cancer cell proliferation and immune evasion. Despite their potential for treating many different types of cancer, the effectiveness of PROTACs in the clinic has been dampened by their dismal cell membrane permeabilities. My project will seek to engineer antibodies targeting PROTACs for internalization into cells to maximize their clinical efficacy.